Shopping Cart
- Remove All
- Your shopping cart is currently empty
dFKBP-1 is a potent PROTAC-based FKBP12 degrader incorporating the FKBP12 ligand SLF, the Thalidomide-based cereblon ligand, and a linker[1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | Inquiry | Backorder | |
500 mg | Inquiry | Backorder |
Description | dFKBP-1 is a potent PROTAC-based FKBP12 degrader incorporating the FKBP12 ligand SLF, the Thalidomide-based cereblon ligand, and a linker[1]. |
In vitro | dFKBP-1 significantly reduces FKBP12 levels in MV4;11 cells, achieving over an 80% decrease at 0.1 μM and a 50% decrease at 0.01 μM. Similarly to dBET1, dFKBP-1's effect on FKBP12 destabilization can be reversed by pre-treatment with Carfilzomib, MLN4924, free SLF, or free Thalidomide. The mechanism of Cereblon (CRBN)-dependent degradation was confirmed using established isogenic 293FT cell lines, both wild-type (293FT-WT) and CRBN-deficient (293FT-CRBN?/?). dFKBP-1 treatment led to a potent and dose-dependent decrease in FKBP12 in 293FT-WT cells, with no impact observed on 293FT-CRBN?/? cells[1]. |
Molecular Weight | 1009.11 |
Formula | C53H64N6O14 |
Cas No. | 1799711-22-0 |
Relative Density. | 1.298 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.